Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of NMS-03305293 plus temozolomide in recurrent glioblastoma
NL-OMON60116Phase 2Completed
- Sponsor
- Nerviano Medical Sciences
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of itareparib in glioblastoma (GBM) and diffuse midline glioma (DMG) (2 arms), sponsored by Nerviano Medical Sciences. Primary endpoints: First cycle dose-limiting toxicities and Objective response rate. Started Jan 2022; status: completed.
02
Drugs
itareparib
03
Conditions
glioblastoma (GBM)diffuse midline glioma (DMG)
Beyond the preview
Go deeper on NL-OMON60116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60116.